Research and development facility
Brazilian pharmaceutical firm Biolab Farmacêutica has opened a new research and development (R&D) centre in Mississauga in the Greater Toronto Area (GTA) of Ontario, Canada.
Developed as part of a global expansion plan, the project will strengthen the work of the company’s São Paulo facility, which is located in Itapecerica da Serra, Brazil.
Constructed at a cost of C$56m ($45m), the new centre is the first R&D facility built by the company outside Brazil. Construction commenced in August 2015 and the inauguration ceremony was held in October 2017.
Biolab collaborated with the Ontario Investment Office, City of Mississauga, Toronto Global and the Brazil-Canada Chamber of Commerce (BCCC) for the development of the R&D facility.
Biolab decided to build its new R&D facility in the GTA due to various available partnership opportunities.
Ontario’s life sciences industry also offered several advantages, including partnership opportunities with universities, laboratories and international research centres.
The new 1,300m² R&D centre in Canada will support the currently ongoing research activities of Biolab’s R&D centre in Brazil.
Research and innovation activities will commence in 2018 after the facility is validated by Canadian authorities, including steps such as testing equipment, documentation creation and compliance with Health Canada standards.
The R&D centre will initially employ a team of 20 scientists and pharmaceutical specialists, which is expected to increase to 60 researchers over the first year.
The new facility will carry out research for a wide range of products in Biolab’s pipeline. The exact number of products has not been finalised yet.
Biolab plans to initially focus on products with commercial potential in both Brazil and Canada.
The Ontario Government provided $2.8m for the new R&D facility through the Jobs and Prosperity Fund, which was created in 2013 to promote R&D activity and finance projects related to clinical trials and pharmaceutical research.
The fund helps reduce 15% in income tax for the beneficiary companies.
Established in 1997, Biolab develops healthcare solutions through the research, development and production of drugs in cardiology, gynaecology, orthopaedics, rheumatology, paediatrics and dermatology sectors.
The company has more than 100 products in its portfolio and has filed 270 patent applications. It has the potential to generate 100 million units of drugs and cosmetic products a year.
Biolab employs 2,600 people at its Brazilian facility and operates a business development office in Miami, Florida. The company also has presence in international markets through the licensing of its products and collaborations with universities, and national and international research laboratories.
An estimated 50% of the revenue generated by the company is from its innovative medicines. Biolab invests 10% of the net revenue generated a year in research, development and innovation.
Biolab is already present in international markets through the licensing of its products. It plans to open a manufacturing facility in Canada by 2021.
Lonza announced the expansion of its bioconjugation facility at its Visp site in Switzerland in December 2020. The expansion will…
Thermo Fisher Scientific (Thermo Fisher) will establish a new pharmaceutical services facility for integrated biologics and sterile drug development and…
Lykan Bioscience opened a purpose-built SMART Manufacturing™ facility for developing cell-based therapies in Hopkinton, Massachusetts, US, in September 2020. The…